Cameron’s Law
Do you support it?
Want to know if it passes?
We'll email you when HR 6238 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on HR 6238.
You're tracking HR 6238
We'll email you the moment it moves.
HR 6238 — Cameron’s Law
Last action — Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
✓In Committee
-
Died in session
This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
Increases the rate of the tax credit for clinical testing expenses for rare diseases or conditions from 25% to 50% (orphan drug tax credit). The bill also requires the Centers for Disease Control and Prevention to complete a study and report on enhancing and expanding the infrastructure to track the epidemiology of rare diseases or conditions.
Bill Text
We don't have the full text on file for this bill yet.
Read HR 6238 on the official United States source →Action History
-
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
-
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
-
Introduced in House
Sponsors
- Josh Gottheimer · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 546 not signed on
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (546)
546 members have not signed on to this bill.
Show all 546 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HR 6238 do?
- Increases the rate of the tax credit for clinical testing expenses for rare diseases or conditions from 25% to 50% (orphan drug tax credit). The bill also requires the Centers for Disease Control and Prevention to complete a study and report on enhancing and expanding the infrastructure to track the epidemiology of rare diseases or conditions.
- Who sponsors HR 6238?
- HR 6238 is sponsored by Josh Gottheimer (D).
- What is the current status of HR 6238?
- This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track HR 6238?
- Track HR 6238 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HR 6238
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HR 6238
Last checked for changes about 17 hours ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →